Standard Dose of Dapagliflozin
The normal adult dose of dapagliflozin is 5 mg once daily for glycemic control in type 2 diabetes, which can be increased to 10 mg once daily if additional glucose lowering is needed; for cardiovascular and renal protection indications (heart failure, chronic kidney disease), the standard dose is 10 mg once daily. 1
Dosing by Indication
For Type 2 Diabetes (Glycemic Control)
- Starting dose: 5 mg orally once daily
- Maximum dose: 10 mg orally once daily for additional glycemic control
- Renal considerations:
- Use standard dosing if eGFR ≥45 mL/min/1.73 m²
- Not recommended for glycemic control if eGFR <45 mL/min/1.73 m² (ineffective due to mechanism of action) 1
For Cardiovascular and Renal Protection
Standard dose is 10 mg once daily for:
- Chronic kidney disease at risk of progression (to reduce sustained eGFR decline, ESKD, CV death, and heart failure hospitalization)
- Heart failure (to reduce CV death, hospitalization, and urgent visits)
- Type 2 diabetes with established cardiovascular disease or multiple CV risk factors (to reduce heart failure hospitalization) 1
Renal considerations for non-glycemic indications:
- Use 10 mg once daily if eGFR ≥25 mL/min/1.73 m²
- Do not initiate if eGFR <25 mL/min/1.73 m²
- May continue 10 mg daily if eGFR falls below 25 while already on treatment 1
Pediatric Dosing
For patients aged 10 years and older with type 2 diabetes:
- Same dosing as adults: start 5 mg once daily, may increase to 10 mg once daily 1
Important Clinical Considerations
Withhold dapagliflozin at least 3 days before major surgery or prolonged fasting to reduce diabetic ketoacidosis risk. Resume when clinically stable and oral intake restored 1
The 2025 ADA guidelines support SGLT2 inhibitors like dapagliflozin as having intermediate to high glucose-lowering efficacy with cardiovascular and renal benefits demonstrated for dapagliflozin specifically 2. Research confirms the 10 mg dose produces approximately 41 grams of urinary glucose excretion over 24 hours at steady state, with minimal drug accumulation and a half-life of 10-12 hours 3.
Common pitfall: Discontinuing dapagliflozin when eGFR declines acutely—an initial eGFR dip of >10% within 2 weeks is common and does not predict worse long-term kidney outcomes; in fact, patients experiencing this acute dip had slower long-term eGFR decline (-1.58 vs -2.44 mL/min/1.73 m²/year) 4.